MB 7133

Drug Profile

MB 7133

Alternative Names: MB-07133

Latest Information Update: 15 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Chiva Pharmaceuticals; Ligand Pharmaceuticals
  • Class Antineoplastics; Furans; Phosphorus compounds; Pyrimidines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatocellular carcinoma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Sep 2015 MB 7133 is in development for Hepatocellular carcinoma in Asia
  • 23 Jan 2015 Phase-III clinical trials in Hepatocellular carcinoma in China (IV) prior to January 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top